CYP27A1 and hepatocellular carcinoma: The study concluded that alternative pathways of BA synthesis are upregulated in advanced stages of liver disease, and that CYP27A1 increases the production of the endogenous agonists 25-oxysterol (25-OHC) and 26-oxysterol (26-OHC), which activates the liver X receptor (LXR), promotes the expression of liposynthesis enzymes, and affects the collection of fats in the liver, resulting in NASH and accelerating the development of HCC [62].